SEC Tracker
Get the app

Klotho Neurosciences GRML

Klotho Neurosciences (KLTOW) filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational activities. The filing highlights Klotho's progress in advancing its pipeline of novel neuroscience therapies, a critical area for investors tracking the company's long-term growth potential. This periodic report is essential for monitoring Klotho's short-term trends and overall business health between annual filings.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when Klotho Neurosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Cue Biopharma CUE public float $52M, Jun 30, 2025
  2. Avalo Therapeutics AVTX public float $54M, Jun 30, 2025
  3. Fitlife Brands FTLF public float $51M, Jun 30, 2025
  4. Immucell ICCC public float $51M, Jun 30, 2025
  5. iBio IBIO public float $58M, Dec 31, 2025